NewAmsterdam Pharma beat EPS and revenue estimates by $0.30 and $4.11M.
Context
What happened: NewAmsterdam Pharma (NAMS) reported Q3 GAAP EPS of -$0.14 and revenue of $19.16M, both above estimates.
Key numbers: EPS -$0.14, beat by $0.30. Revenue $19.16M, up 5374.3% Y/Y, beat by $4.11M. Cash, cash equivalents and marketable securities $643.1M as of September 30, 2026, versus $728.9M as of December 31, 2025.
Why it matters: Both the EPS and revenue figures came in ahead of consensus estimates, and revenue rose sharply year over year.
Coverage: 4 outlets in 24h